|
Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study. |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Roche |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Honoraria - Amgen; AstraZeneca; Celgene; Lilly; NanoString Technologies; Novartis; Roche |
Consulting or Advisory Role - Accelsiors |
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Celgene; Ipsen; Lilly; Medtronic; Novartis; Pfizer |
|
|
Honoraria - Pfizer; Roche |
Consulting or Advisory Role - Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst) |
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Teva (Inst); Vifor Pharma (Inst) |
|
|
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
Other Relationship - UpToDate |